Pharmacogenomic Biomarker Study for Recombinant Human Activated Protein C Treatment in Severe Sepsis

Septic Shock Clinical Trial

Official title:

A Multicenter Pharmacogenomic Biomarker Study in Matched Patients With Severe Sepsis Treated With or Without Recombinant Human Activated Protein C [Xigris®, Drotrecogin Alfa (Activated)]

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01486524
• Other study ID #: SGX301
• Status: Active, not recruiting
• Phase: N/A
• First received: December 2, 2011
• Last updated: December 5, 2011
• Start date: October 2011
• Est. completion date: April 2012

Study information

• Verified date: December 2011
• Source: Sirius Genomics Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The overall purpose of the study is to determine whether either of the Improved Response Polymorphisms (IRPs) individually predicts a differential DrotAA treatment effect in patients with severe sepsis and high risk of death. This will be an international, multicenter, "prospective-retrospective", nonrandomized, controlled, outcome-blinded, genotype-blinded, matched-patients study. No prospective enrollment or treatment of patients will occur under this protocol. Retrospectively collected clinical data and DNA samples will be analyzed for existing cohorts of patients with severe sepsis who were previously treated with DrotAA (treatment group) or not (control group) as part of their standard care in an ICU.

Description:

This will be a multicenter, "prospective-retrospective", controlled, matched-patients study. Retrospective phenotypic data and DNA samples will be obtained from patient registries and clinical trials where the study hypotheses were not related to DrotAA treatment. The prospective aspect of this study will be the statistical testing of prespecified hypotheses regarding the IRP genotype as a predictive biomarker for differential DrotAA treatment effects.

To control for differences in standard of care in different countries and medical centers, the selection of matched control patients will be performed within each cohort. Control patients will be selected to match the DrotAA-treated patients using an algorithm that matches on baseline demographic and disease characteristics that may have influenced the decision to give DrotAA or that may impact survival. A propensity score (the likelihood for having received DrotAA treatment) will be derived using the matching variables that are common in all cohorts. The number of matched control patients for each treated patient will be variable, up to a maximum of 3.

The selection of the control patients via the matching algorithm will be conducted by an independent clinical research organization (CRO) in a blinded manner - specifically without knowledge of survival outcome, other outcome data, and genotype. A two-phase transfer of data from each center will be implemented to ensure that the selection of matched control patients is implemented in a blinded manner. The first step will involve the transfer of the baseline data for all variables needed to conduct the matching. Once the control patients have been identified for each cohort, the outcomes data will be transferred to the CRO in the second phase of data transfer.

Centralized genotyping using a validated Taqman®-based analytical method will be conducted on the DNA samples for all matched patients. The genotyping laboratory will be blinded to treatment and outcome.

The total number of patients in the available cohorts is >23,000, with approximately 800 who have received DrotAA as part of their standard ICU-based care. After applying eligibility criteria to all patients and selecting the matched control patients, it is expected that the final analysis will include approximately 3000 patients.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 3000
• Est. completion date: April 2012
• Est. primary completion date: April 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria for INDICATED population:

1. Age = 18 years

2. Severe sepsis (must meet a, b, and c below)

• Suspected or proven infection

• Systemic Inflammatory Response Syndrome (SIRS)(must meet 2 of 4 criteria)

• Temperature < 36°C or > 38°C

• Heart rate > 90 beats/minute

• Respiratory rate > 20 breaths/minute or PaC02 < 32 mm Hg) or on mechanical ventilation

• White blood cell count < 4,000/mm3 or > 12,000/mm3

• At least one organ dysfunction due to sepsis based on definitions of clinically significant organ dysfunction

• Cardiovascular dysfunction [must meet one of (1), (2), or (3) below]:

• Systolic blood pressure = 90 mmHg and pH = 7.3

• Mean arterial pressure = 70 mmHg and pH = 7.3

• Reported use of a vasopressor alone is sufficient evidence of shock

• Pulmonary dysfunction: PaO2/FiO2 = 300 mmHg

• Central Nervous System dysfunction: Glasgow Coma Scale = 12

• Coagulation dysfunction: platelets = 80,000/mm3

• Renal dysfunction: creatinine = 2.0 mg/dL

• Hepatic dysfunction: bilirubin = 2.0 mg/dL

3. High risk of death (one of a, b, or c below)

• APACHE II = 25

• SAPS II = 54

• Multiple organ dysfunction - two or more clinically significant organ dysfunctions (as defined above), which have occurred within 2 days of each other

4. Platelet counts = 30,000/mm3

5. DrotAA status known

Exclusion Criteria:

1. Patients with no DNA

2. Patients enrolled in local cohort more than 2 years before Xigris [drotrecogin alfa activated)] was commercially available

A secondary analysis population with severe sepsis will be defined by Inclusion Criteria 1, 2, 4, and 5 above, and the Exclusion Criteria. This will be referred to as the SEVSEP population.

Study Design

Time Perspective: Retrospective

Related Conditions & MeSH terms

• Sepsis
• Septic Shock
• Severe Sepsis

Locations

Country	Name	City	State
Canada	University of British Columbia and Providence Health Care, St. Paul's Hospital	Vancouver	British Columbia
France	University of Versailles, Hospital Raymond Poincaré (AP-HP)	Garches
France	Université Paris Descartes, Sorbonne Paris Cité, Cochin Hotel-Dieu University Hospital	Paris
United Kingdom	Imperial College London, Charing Cross Hospital	London
United States	Emory University School of Medicine	Atlanta	Georgia
United States	Johns Hopkins University, Bayview Medical Center	Baltimore	Maryland
United States	Harvard University School of Public Health	Boston	Massachusetts
United States	Vanderbilt University Schoo of Medicine	Nashville	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
Sirius Genomics Inc.

Countries where clinical trial is conducted

United States,  Canada,  France,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	In-hospital mortality through Day 28	All cause in-hospital mortality up to Day 28 or discharge, whichever comes first. Day 1 is the day when patient meets eligibility criteria for this study.	Through Day 28.	No
Secondary	Time to death in hospital	Time to death (any cause) in hospital, censored by the competing risk of discharge from hospital	Through Day 28	No
Secondary	Time to death	Time to death (any cause), censored at Day 60 or last evaluation. Will be evaluated using data from centers where follow-up extended beyond hospital discharge.	Through Day 60	No
Secondary	Mechanical ventilator-free days through Day 28	Number of days alive and free of mechanical ventilation from Day 1 through Day 28.	Through Day 28	No
Secondary	ICU-free days through Day 28	Number of days alive and free of ICU from Day 1 through Day 28.	Through Day 28	No
Secondary	Hospital-free days through Day 28	Number of days alive and free of hospitalization from Day 1 through Day 28.	Through Day 28	No
Secondary	ICU length of stay		Through Day 180	No
Secondary	Hospital length of stay		Through Day 180	No